What is Corvus Pharmaceuticals's PP&E sale proceeds?

Corvus Pharmaceuticals (CRVS) reported PP&E sale proceeds of $1.25K in Q4 2024.

What does PP&E sale proceeds mean?

Cash received from selling property, plant, and equipment no longer needed for operations.

Candel Therapeutics, Inc.CADL

$6.75K—

Operating income-$14.9M-49.9%

Net income-$13.7M-190%

EPS (diluted)-$0.15-15.4%

Cash & equivalents$40.1M+702%

Total debt$834.0K-27.7%

Total equity$240.7M+388%

Total assets$253.2M+326%

Operating cash flow-$10.4M-25.5%

CapEx$91.0K+153%

Free cash flow-$10.5M-26.1%

Market cap$1.1B+259%

Enterprise value$1.06B+251%

Return on equity-30.5%-12.5pp

Debt / equity0×0.0×

Current ratio19.8×+14.9×

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Corvus Pharmaceuticals’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Corvus Pharmaceuticals's PP&E sale proceeds?: Corvus Pharmaceuticals (CRVS) reported PP&E sale proceeds of $1.25K in Q4 2024.
What does PP&E sale proceeds mean?: Cash received from selling property, plant, and equipment no longer needed for operations.